|Articles|April 1, 1998

April 1998
Volume 4
Issue 4

Alzheimer's Disease: Clinical Features and Pharmacologic Management

Author(s)Andrea S. Franks, PharmD, BCPS, W. Nathan Rawls, PharmD

Download PDF: Alzheimer's Disease: Clinical Features and Pharmacologic Management

Articles in this issue

over 28 years ago

Article

Cost of Migraine Management: A Pharmacoeconomic Overview

over 28 years ago

Article

A Program to Reduce Discharge Delays in a Neonatal Intensive Care Unit

over 28 years ago

Article

Attitudes and Behavioral Intentions Regarding Managed Care: A Comparison of Academic and Community Physicians

over 28 years ago

Article

Physician and Dietitian Prescribing of a Commercially Available Oral Nutritional Supplement

over 28 years ago

Article

A New Gatekeeper for Back Pain

over 28 years ago

Article

Influencing Physicians: The Three Critical Elements of a Successful Strategy

over 28 years ago

Article

Medicare HMOs: Who Joins and Who Leaves?

over 28 years ago

Article

Changes in Benefit Payments and Health Insurance Premiums Among Firms Switching Health Insurance Carriers

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Alzheimer's Disease: Clinical Features and Pharmacologic Management

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Alzheimer's Disease: Clinical Features and Pharmacologic Management

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer